Milestone Pharmaceuticals sells CARDAMYST, a nasal spray for treating a rapid heartbeat condition called PSVT. MIST reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | Cantor Fitzgerald | Initiated | Buy |
Seasonality
How MIST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in MIST in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIST is in one of them and how their past MIST trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MIST in an article yet. Here's the latest on the wider market.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company based in Montreal, Quebec, Canada, that develops heart medicines. Its main product is CARDAMYST, a nasal spray containing etripamil that patients can use themselves to stop an episode of PSVT, a condition that causes the heart to suddenly beat too fast. The product is sold in the United States through retail pharmacies, and the company is developing etripamil for atrial fibrillation as well. Its customers are patients and the doctors, mainly cardiologists, who prescribe its medicines.
- Headquarters
- Montreal, Quebec, Canada